Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.

Leukemia - 1 Sept 2005

Nanri T, Matsuno N, Kawakita T, Mitsuya H, Asou N

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Chromosomes, Human, Pair 16
Share to Imatinib Mesylate
Share to Neoplasm, Residual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Remission Induction

Source

Identifiers

PMID: 16049512
DOI: 10.1038/sj.leu.2403889

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Imatinib mesylate for refractory acute myeloblastic leukemia harboring inv(16) and a C-KIT exon 8 mutation.PMID 16049512Read ↗

Metastatic gastrointestinal stromal tumor with an exon 11 c-kit mutation responding to the tyrosine kinase inhibitor imatinib.Semantic proximity Read ↗

Imatinib resistance in chronic myeloid leukemia due to a rare mutation.Semantic proximity Read ↗

Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogeneSemantic proximity Read ↗

Relapsed childhood acute myeloid leukemia patient with inversion of chromosome 16 harboring a low FLT3 internal tandem duplication allelic burden and KIT mutations.Semantic proximity Read ↗

BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.Semantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.Semantic proximity Read ↗

Specific Targeted Therapy of Chronic Myelogenous Leukemia with ImatinibSemantic proximity Read ↗

Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a case reportSemantic proximity Read ↗

c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia.Semantic proximity Read ↗

Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.Semantic proximity Read ↗

Avapritinib is Effective for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia with t (8;21) and KIT mutation Failing to Immunotherapy After Allogeneic Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycinSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.